RECEIVED
CENTRAL FAX CENTER
NOV 27 2006

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Currently amended) A compound of formula I:



(I)

or a pharmaceutically acceptable salt thereof, wherein:

E' is [|–CO- or|] $–SO_2$-;

A is selected from -R^1-C_1-C_6 alkyl, which is optionally substituted with one or more groups independently selected from hydroxy, C_1-C_4 alkoxy, Ht, -O-Ht, -NR^2-CO-$N(R^2)_2$, -SO_2-R^2 or -CO-$N(R^2)_2$; or -R^1-C_2-C_6 alkenyl, which is optionally substituted with one or more groups independently selected from hydroxy, C_1-C_4 alkoxy, Ht, -O-Ht, -NR^2-CO-$N(R^2)_2$ or -CO-$N(R^2)_2$; or R^7;

R^1 is -O-C(O)- ;

each Ht is independently selected from C_3-C_7 cycloalkyl; C_5-C_7 cycloalkenyl; C_6-C_{14} aryl; or a 5-7 membered saturated or unsaturated heterocycle, containing one or more heteroatoms selected from N, O, or S; wherein said aryl or said heterocycle is optionally fused to Q; and wherein any member of said Ht is optionally substituted with one or more substituents independently selected from oxo, -OR^2, SR^2, -R^2, -$N(R^2)(R^2)$, -R^2-OH, -CN, -CO_2R^2, -C(O)-$N(R^2)_2$, -$S(O)_2$-$N(R^2)_2$, -$N(R^2)$-C(O)-R^2, -$N(R^2)$-C(O)O-R^2, -C(O)-R^2, -$S(O)_n$-R^2, -OCF_3, -$S(O)_n$-Q, methylenedioxy, -$N(R^2)$-$S(O)_2(R^2)$, halo, -CF_3, -NO_2, Q, -OQ, -OR^7, -SR^7, -R^7, -$N(R^2)(R^7)$ or -$N(R^7)_2$;

each Q is independently selected from a 3-7 membered saturated, partially saturated or unsaturated carbocyclic ring system; or a 5-7 membered saturated, partially saturated or unsaturated heterocyclic ring containing one or more heteroatoms selected from O, N, or S; wherein Q is optionally substituted with one or more groups selected from oxo, $-OR^2$, $-R^2$, $-SO_2R^2$, $-SO_2-N(R^2)_2$, $-N(R^2)_2$, $-N(R^2)-C(O)-R^2$, $-R^2-OH$, -CN, $-CO_2R^2$, $-C(O)-N(R^2)_2$, halo, $-CF_3$;

each R^2 is independently selected from H, or C_1-C_4 alkyl,; and wherein said alkyl, when not a substituent of Q, is optionally substituted with Q or $-OR^3$; wherein when said R^2 is an $-OR^3$ substituted moiety, said R^3 in $-OR^3$ may not be $-OR^2$ substituted;

B **is absent** ~~, when present, is $-N(R^2)-C(R^3)_2-C(O)-$~~ ;

each x is independently 0 or 1;

each R^3 is independently selected from H, Ht, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_3-C_6 cycloalkyl or C_5-C_6 cycloalkenyl; wherein any member of said R^3, except H, is optionally substituted with one or more substituents selected from $-OR^2$, $-C(O)-NH-R^2$, $-S(O)_n-N(R^2)(R^2)$, $-N(R^2)_2$, $-N(R^2)-C(O)-O(R^2)$, $-N(R^2)-C(O)-N(R^2)$, $-N(R^2)-C(O)-(R^2)$, Ht, -CN, $-SR^2$, $-CO_2R^2$, or $NR^2-C(O)-R^2$;

each n is independently 1 or 2;

G **is H** ~~, when present, is selected from H, R^7 or C_1-C_4 alkyl, or, when G is C_1-C_4 alkyl, G and R^7 are optionally bound to one another either directly or through a C_1-C_3 linker to form a heterocyclic ring; or~~

~~when G is not present, the nitrogen to which G is attached is bound directly to the R^7 group in $-OR^7$ with the concomitant displacement of one ZM group from R^7;~~

D is ~~selected from Q;~~ C_1-C_6 alkyl optionally substituted with ~~one or more groups selected from C_3-C_6 cycloalkyl, $-OR^2$, S Ht, $-R^3$, O Q or~~ Q; ~~C_2-C_4 alkenyl optionally substituted with one or more groups selected from $-OR^2$, S Ht, $-R^3$, O Q or Q; C_3-C_6~~

~~cycloalkyl optionally substituted with or fused to Q; or C_5-C_6-cycloalkenyl optionally substituted with or fused to Q;~~

D' is selected from C_1-C_{15} alkyl, C_2-C_{15} alkenyl or C_2-C_{15} alkynyl, each of which contains one or more substituents selected from oxo, **[[halo,]]** $-CF_3$, $-OCF_3$, $-NO_2$, azido, -SH, **[[-SR^3,]]** $-N(R^3)-N(R^3)_2$, $-O-N(R^3)_2$, $-(R^3)N-O-(R^3)$, **[[-$N(R^3)_2$,]]** -CN, $-CO_2R^3$, $-C(O)-N(R^3)_2$, $-S(O)_n-N(R^3)_2$, $-N(R^3)-C(O)-R^3$, $-N(R^3)-C(O)-N(R^3)_2$, $-N(R^3)-C(O)-S(R^3)$, $-C(O)-R^3$, **[[-$S(O)_n-R^3$,]]** $-N(R^3)-S(O)_n(R^3)$, $-N(R^3)-S(O)_n-N(R^3)_2$, $-S-NR^3-C(O)R^3$, $-C(S)N(R^3)_2$, $-C(S)R^3$, $-NR^3-C(O)OR^3$, $-O-C(O)OR^3$, $-O-C(O)N(R^3)_2$, $-NR^3-C(S)R^3$, =N-OH, $=N-OR^3$, $=N-N(R^3)_2$, $=NR^3$, $=NNR^3C(O)N(R^3)_2$, $=NNR^3C(O)OR^3$, $=NNR^3S(O)_n-N(R^3)_2$, $-NR^3-C(S)OR^3$, $-NR^3-C(S)N(R^3)_2$, $-NR^3-C[=N(R^3)]-N(R^3)_2$, $-N(R^3)-C[=N-NO_2]-N(R^3)_2$, $-N(R^3)-C[=N-NO_2]-OR^3$, $-N(R^3)-C[=N-CN]-OR^3$, $-N(R^3)-C[=N-CN]-(R^3)_2$, $-OC(O)R^3$, $-OC(S)R^3$, $-OC(O)N(R^3)_2$, $-C(O)N(R^3)-N(R^3)_2$, $-O-C(O)N(R^3)-N(R^3)_2$, $O-C(O)N(OR^3)(R^3)$, $N(R^3)-N(R^3)C(O)R^3$, $N(R^3)-OC(O)R^3$, $N(R^3)-OC(O)R^3$, $N(R^3)-OC(O)R^3$, $-OC(S)N(R^3)_2$, $-OC(S)N(R^3)(R^3)$, or PO_3-R^3; ~~with the proviso that when R^2 is H, E' is $-SO_2$, G is H or alkyl, and when B is present or when B is not present and R^1 is C(O), D' may not be C_1-C_{15} alkyl substituted with one substituent selected from $-N(R^3)_2$, $-SR^3$ or $-S(O)_n-R^3$, or substituted with two $-N(R^3)_2$ substituents;~~

E is selected from Ht; O-Ht; Ht-Ht; Ht fused with Ht; $-O-R^3$; $-N(R^2)(R^3)$; C_1-C_6 alkyl optionally substituted with one or more groups selected from R^4 or Ht; C_2-C_6 alkenyl optionally substituted with one or more groups selected from R^4 or Ht; C_3-C_6 saturated carbocycle optionally substituted with one or more groups selected from R^4 or Ht; or C_5-C_6 unsaturated carbocycle optionally substituted with one or more groups selected from R^4 or Ht;

each R^4 is independently selected from $-OR^2$, $-OR^3$, $-SR^2$, $-SOR^2$, $-SO_2R^2$, $-CO_2R^2$, $-C(O)-NHR^2$, $-C(O)-N(R^2)_2$, $-C(O)-NR^2(OR^2)$, $-S(O)_2-NHR^2$, halo, $-NR^2-C(O)-R^2$, $-N(R^2)_2$ or –CN; **and**

each R^7 is ~~independently selected from~~ hydrogen, **[[**,



;]]

~~wherein each M is independently selected from H, Li, Na, K, Mg, Ca, Ba, $N(R^2)_4$, C_1-C_{12}-alkyl, C_2-C_{12}-alkenyl, or R^6; wherein 1 to 4 CH_2 radicals of the alkyl or alkenyl group, other than the CH_2 that is bound to Z, is optionally replaced by a heteroatom group selected from O, S(O), $S(O)_2$, or $N(R^2)$; and wherein any hydrogen in said alkyl, alkenyl or R^6 is optionally replaced with a substituent selected from oxo, OR^2, R^2, $N(R^2)_2$, $N(R^2)_3$, R^2OH, CN, CO_2R^2, $C(O)N(R^2)_2$, $S(O)_2N(R^2)_2$, $N(R^2)C(O)R^2$, $C(O)R^2$, $S(O)_nR^2$, OCF_3, $S(O)_nR^6$, $N(R^2)S(O)_2(R^2)$, halo, CF_3, or NO_2;~~

~~M' is H, C_1-C_{12}-alkyl, C_2-C_{12}-alkenyl, or R^6; wherein 1 to 4 CH_2 radicals of the alkyl or alkenyl group is optionally replaced by a heteroatom group selected from O, S, S(O), $S(O)_2$, or $N(R^2)$; and wherein any hydrogen in said alkyl, alkenyl or R^6 is optionally replaced with a substituent selected from oxo, OR^2, R^2, $N(R^2)_2$, $N(R^2)_3$, R^2OH, CN, CO_2R^2, $C(O)N(R^2)_2$, $S(O)_2N(R^2)_2$, $N(R^2)C(O)R_2$, $C(O)R^2$, $S(O)_nR^2$, OCF_3, $S(O)_nR^6$, $N(R^2)S(O)_2(R^2)$, halo, CF_3, or NO_2;~~

~~Z is O, S, $N(R^2)_2$, or, when M is not present, H.~~

~~Y is P or S;~~

~~X is O or S;~~

~~R^9 is $C(R^2)_2$, O or $N(R^2)$; and wherein when Y is S, Z is not S;~~

~~R^6 is a 5-6 membered saturated, partially saturated or unsaturated carbocyclic or heterocyclic ring system, or an 8-10 membered saturated, partially saturated or unsaturated bicyclic ring system; wherein any of said heterocyclic ring systems contains one or more heteroatoms selected from O, N, S, $S(O)_n$ or $N(R^2)$; and wherein any of said ring systems optionally contains 1 to 4 substituents independently selected from OH, C_1-C_4-alkyl, O-C_1-C_4 alkyl or O-C(O)-C_1-C_4-alkyl; and~~

~~each R^5 is independently selected from hydrogen, C_1-C_8-alkyl, C_2-C_8-alkenyl, C_2-C_8 alkynyl or Ht, wherein any R^5, except for hydrogen, is optionally substituted with CF_3, PO_3R^3, azido or halo.~~

2. (Currently amended) The compound according to claim 1, having the formula IA:



(IA)

wherein:

D' is selected from C_{1-15} alkyl, C_{2-15} alkenyl or C_2-C_{15} alkynyl; each of which is substituted with one to two –CN groups and ~~each of which~~ is optionally substituted with C_3-C_8 cycloalkyl.

3. (Currently amended) The compound according to claim 2 wherein:

D' is selected from C_{1-15} alkyl or C_{2-15} alkenyl; each of which is substituted with one to two –CN groups and ~~each of which~~ is optionally substituted with C_3-C_8 cycloalkyl.

4. (Currently amended) The compound according to claim 2 wherein:

D' is C_2-C_{15} alkynyl which is substituted with one to two –CN groups and ~~each of which~~ is optionally substituted with C_3-C_8 cycloalkyl.

5. (Currently amended) The compound according to claim 1 having the formula IB:



(IB)

wherein:

D' is selected from C_1-C_{15} alkyl, C_2-C_{15} alkenyl or C_2-C_{15} alkynyl, each of which contains one or more substituents selected from oxo, **[[halo,]]** $-CF_3$, $-OCF_3$, $-NO_2$, azido, -SH, **[[-SR^3,]]** $-N(R^3)-N(R^3)_2$, $-O-N(R^3)_2$, $-(R^3)N-O-(R^3)$, **[[-$N(R^3)_2$,]]** $-CO_2R^3$, $-C(O)-N(R^3)_2$, $-S(O)_n-N(R^3)_2$, $-N(R^3)-C(O)-R^3$, $-N(R^3)-C(O)-N(R^3)_2$, $-N(R^3)-C(O)-S(R^3)$, $-C(O)-R^3$, **[[-$S(O)_n-R^3$,]]** $-N(R^3)-S(O)_n(R^3)$, $-N(R^3)-S(O)_n-N(R^3)_2$, $-S-NR^3-C(O)R^3$, $-C(S)N(R^3)_2$, $-C(S)R^3$, $-NR^3-C(O)OR^3$, $-O-C(O)OR^3$, $-O-C(O)N(R^3)_2$, $-NR^3-C(S)R^3$, =N-OH, $=N-OR^3$, $=N-N(R^3)_2$, $=NR^3$, $=NNR^3C(O)N(R^3)_2$, $=NNR^3C(O)OR^3$, $=NNR^3S(O)_n-N(R^3)_2$, $-NR^3-C(S)OR^3$, $-NR^3-C(S)N(R^3)_2$, $-NR^3-C[=N(R^3)]-N(R^3)_2$, $-N(R^3)-C[=N-NO_2]-N(R^3)_2$, $-N(R^3)-C[=N-NO_2]-OR^3$, $-N(R^3)-C[=N-CN]-OR^3$, $-N(R^3)-C[=N-CN]-(R^3)_2$, $-OC(O)R^3$, $-OC(S)R^3$, $-OC(O)N(R^3)_2$, $-C(O)N(R^3)-N(R^3)_2$, $-O-C(O)N(R^3)-N(R^3)_2$, $O-C(O)N(OR^3)(R^3)$, $N(R^3)-N(R^3)C(O)R^3$, $N(R^3)-OC(O)R^3$, $N(R^3)-OC(O)R^3$, $N(R^3)-OC(O)R^3$, $-OC(S)N(R^3)_2$, $-OC(S)N(R^3)(R^3)$, or PO_3-R^3~~; with the proviso that when R^2 is H, E' is $-SO_2-$, G is H or alkyl, and when B is present or when B is not present and R^1 is $-C(O)-$, D' may not be C_1-C_{15} alkyl substituted with one substituent selected from $-N(R^3)_2$, $-SR^3$ or $-S(O)_n-R^3$, or substituted with two $-N(R^3)_2$ substituents.~~

6. (Currently amended) The compound according to claim 5 wherein:

D' is selected from C_1-C_{15} alkyl or C_2-C_{15} alkenyl, each of which contains one or more substituents selected from oxo, **[[halo,]]** $-CF_3$, $-OCF_3$, $-NO_2$, azido, $-N(R^3)-N(R^3)_2$, $-O-N(R^3)_2$, $-(R^3)N-O-(R^3)$, **[[-$N(R^3)_2$,]]** $-N(R^3)-C(O)-N(R^3)_2$, $-N(R^3)-C(O)-S(R^3)$, $-C(O)-R^3$, **[[-$S(O)_n-R^3$,]]**

$-N(R^3)-S(O)_n(R^3)$, $-N(R^3)-S(O)_n-N(R^3)_2$, $-S-NR^3-C(O)R^3$, $-C(S)N(R^3)_2$, $-C(S)R^3$, $-NR^3-C(O)OR^3$, $-O-C(O)OR^3$, $-O-C(O)N(R^3)_2$, $-NR^3-C(S)R^3$, =N-OH, $=N-OR^3$, $=N-N(R^3)_2$, $=NR^3$, $=NNR^3C(O)N(R^3)_2$, $=NNR^3C(O)OR^3$, $=NNR^3S(O)_n-N(R^3)_2$, $-NR^3-C(S)OR^3$, $-NR^3-C(S)N(R^3)_2$, $-NR^3-C[=N(R^3)]-N(R^3)_2$, $-N(R^3)-C[=N-NO_2]-N(R^3)_2$, $-N(R^3)-C[=N-NO_2]-OR^3$, $-N(R^3)-C[=N-CN]-OR^3$, $-N(R^3)-C[=N-CN]-(R^3)_2$, $-OC(O)R^3$, $-OC(S)R^3$, $-OC(O)N(R^3)_2$, $-C(O)N(R^3)-N(R^3)_2$, $-O-C(O)N(R^3)-N(R^3)_2$, $O-C(O)N(OR^3)(R^3)$, $N(R^3)-N(R^3)C(O)R^3$, $N(R^3)-OC(O)R^3$, $N(R^3)-OC(O)R^3$, $N(R^3)-OC(O)R^3$, $-OC(S)N(R^3)_2$, $-OC(S)N(R^3)(R^3)$, or PO_3-R^3; C_2-C_{15} alkynyl which contains one or more substituents selected from oxo, **[[halo,]]** $-CF_3$, $-OCF_3$, $-NO_2$, azido, -SH, **[[-SR^3,]]** $-N(R^3)-N(R^3)_2$, $-O-N(R^3)_2$, $-(R^3)N-O-(R^3)$, **[[-$N(R^3)_2$,]]** $-CO_2R^3$, $-C(O)-N(R^3)_2$, $-S(O)_n-N(R^3)_2$, $-N(R^3)-C(O)-R^3$, $-N(R^3)-C(O)-N(R^3)_2$, $-N(R^3)-C(O)-S(R^3)$, $-C(O)-R^3$, **[[-$S(O)_n-R^3$,]]** $-N(R^3)-S(O)_n(R^3)$, $-N(R^3)-S(O)_n-N(R^3)_2$, $-S-NR^3-C(O)R^3$, $-C(S)N(R^3)_2$, $-C(S)R^3$, $-NR^3-C(O)OR^3$, $-O-C(O)OR^3$, $-O-C(O)N(R^3)_2$, $-NR^3-C(S)R^3$, =N-OH, $=N-OR^3$, $=N-N(R^3)_2$, $=NR^3$, $=NNR^3C(O)N(R^3)_2$, $=NNR^3C(O)OR^3$, $=NNR^3S(O)_n-N(R^3)_2$, $-NR^3-C(S)OR^3$, $-NR^3-C(S)N(R^3)_2$, $-NR^3-C[=N(R^3)]-N(R^3)_2$, $-N(R^3)-C[=N-NO_2]-N(R^3)_2$, $-N(R^3)-C[=N-NO_2]-OR^3$, $-N(R^3)-C[=N-CN]-OR^3$, $-N(R^3)-C[=N-CN]-(R^3)_2$, $-OC(O)R^3$, $-OC(S)R^3$, $-OC(O)N(R^3)_2$, $-C(O)N(R^3)-N(R^3)_2$, $-O-C(O)N(R^3)-N(R^3)_2$, $O-C(O)N(OR^3)(R^3)$, $N(R^3)-N(R^3)C(O)R^3$, $N(R^3)-OC(O)R^3$, $N(R^3)-OC(O)R^3$, $N(R^3)-OC(O)R^3$, $-OC(S)N(R^3)_2$, $-OC(S)N(R^3)(R^3)$, or PO_3-R^3; ~~with the proviso that when R^7 is H, E' is $-SO_2-$, G is H or alkyl, and when B is present or when B is not present and R^1 is -C(O)-, D' may not be C_1-C_{15} alkyl substituted with one substituent selected from $-N(R^3)_2$ or $-S(O)_n-R^3$, or substituted with two $-N(R^3)_2$ substituents.~~

7. (Currently amended) The compound according to claim 5 wherein:

D' is selected from C_1-C_{15} alkyl or C_2-C_{15} alkenyl, each of which contains one or more substituents selected from -SH, **[[-SR^3,]]** $-CO_2R^3$, $-C(O)-N(R^3)_2$, $-S(O)_n-N(R^3)_2$ or $-N(R^3)-C(O)-R^3$; ~~with the proviso that when R^7 is H, E' is $-SO_2-$, G is H or alkyl, and when B is present or when B is not present and R^1 is -C(O)-, D' may not be C_1-C_{15} alkyl substituted with one substituent selected from $-SR^3$.~~

8. (Canceled)

9. (Withdrawn) The compound according to any one of claims 1 to 7,

wherein at least one R^7 is selected from:  ,  ,

 , -(L)-lysine, $-PO_3Na_2$,  ,  , -(L)-tyrosine,

 , $-PO_3Mg$, $-PO_3(NH_4)_2$, $-CH_2-OPO_3Na_2$,  , -(L)-serine, $-SO_3Na_2$,

 , $-SO_3Mg$, $-SO_3(NH_4)_2$, $-CH_2-OSO_3Na_2$, $-CH_2-OSO_3(NH_4)_2$,

 ,  ,  ,  ,

 ,  , acetyl,  ,  , -(L)-valine, -(L)-glutamic acid, -

(L)-aspartic acid, -(L)-γ-t-butyl-aspartic acid,  ,

-(L)-(L)-3-pyridylalanine, -(L)-histidine, -CHO,  ,



 ,  ,  , PO_3K_2, PO_3Ca,

PO_3-sperminc, PO_3-(spermidine)$_2$ or PO_3-(meglaminc)$_2$.

10. (Currently amended) The compound according to claim 1[[8]] 1, having the formula II:



(II).

11. (Canceled)

12. (Original) The compound according to claim 10, wherein:

D' is $-CH_2$-R''; and

R'' is selected from



wherein m is 0 to 3.

13. (Original) The compound according to claim 10, wherein E is selected from



14. (Withdrawn) The compound according to claim 10, wherein R^7 is $-PO_3^{2-}$.

15. (Previously presented) The compound according to claim 1, having the formula III:



(III),

wherein x = 1.

16. (Withdrawn) The compound according to claim 1, having the formula IV:



(IV);

wherein $R^{3'}$ is selected from H, Ht, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_3-C_6 cycloalkyl or C_5-C_6 cycloalkenyl; wherein any member of said R^3, except H, is optionally substituted with one or more substituents selected from $-OR^2$, $-C(O)-NH-R^2$, $-S(O)_n-N(R^2)(R^2)$, $-N(R^2)_2$, $-N(R^2)-C(O)-O(R^2)$, $-N(R^2)-C(O)-N(R^2)$, $-N(R^2)-C(O)-(R^2)$, $-N(R^2-OR^2)_2$, -C(O)-Ht, Ht, -CN, $-SR^2$, $-CO_2R^2$, or $NR^2-C(O)-R^2$.

17. (Currently amended) The compound according to claim 1, wherein said compound is selected from any one of compound numbers: 1, 2, 3, 4, 5, 6, 22, 127, 203, 234, 277, 278, 279, 363, and 364;



wherein R^7 is H; and

Compound	R'	R''	E
1			
2			
3			

Compound	R'	R''	E
4			
5			
6			
22			
127			
203			
234			
277			
278			

Compound	R'	R''	E
279			



Compound	R'	E	n	R
363			3	
364			3	

18-22. (Canceled)

23. (Currently amended) A composition comprising a compound according to any one of claims ~~1-10 and 12-17~~ **1-7, 10, 12, 13, 15, and 17** or a pharmaceutically acceptable salt thereof in **a therapeutically effective amount** ~~an amount sufficient to detectably inhibit aspartyl protease activity in a patient~~, and a pharmaceutically acceptable carrier.

24. (Original) The composition according to claim 23, further comprising an additional antiviral agent other than a compound of formula (I).

25. (Original) The composition according to claim 23, wherein said composition is formulated as a pharmaceutically acceptable, orally available tablet or capsule.

26. (Currently amended) A method of treating an HIV virus infection in a human comprising the step of administering to said human a composition according to ~~any one of claims 23 to 25~~ **claim 23**.

27. (Currently amended) The method according to claim 26, **further** comprising the step of

administering to said patient an additional antiviral agent other than a compound of formula I, wherein said additional antiviral agent is administered prior to, simultaneously with or following administration of said composition.

28. (New) A method of treating an HIV virus infection in a human comprising the step of administering to said human a composition according to claim 24.

29. (New) The method according to claim 28, further comprising the step of

administering to said patient a second additional antiviral agent other than a compound of formula I, wherein said second additional antiviral agent is administered prior to, simultaneously with or following administration of said composition.

30. (New) A method of treating an HIV virus infection in a human comprising the step of administering to said human a composition according to claim 25.

31. (New) The method according to claim 30, further comprising the step of administering to said patient an additional antiviral agent other than a compound of formula I, wherein said additional antiviral agent is administered prior to, simultaneously with or following administration of said composition.